These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 12172412)
1. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Andrade RJ; Lucena MI; Fernández MC; Vega JL; García-Cortés M; Casado M; Guerrero-Sanchez E; Pulido-Fernandez F Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):887-90. PubMed ID: 12172412 [TBL] [Abstract][Full Text] [Related]
10. Acute pancreatitis associated with angiotensin II receptor antagonists. Fisher AA; Bassett ML Ann Pharmacother; 2002 Dec; 36(12):1883-6. PubMed ID: 12452749 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study). Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596 [TBL] [Abstract][Full Text] [Related]
12. Acute pancreatitis associated with irbesartan therapy. Famularo G; Minisola G; Nicotra GC; De Simone C Pancreas; 2005 Oct; 31(3):294-5. PubMed ID: 16163066 [No Abstract] [Full Text] [Related]
13. Regression of left ventricular hypertrophy in human hypertension with irbesartan. Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367 [TBL] [Abstract][Full Text] [Related]
14. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I; N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517 [TBL] [Abstract][Full Text] [Related]
15. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency. Descombes E; Fellay G Ren Fail; 2000 Nov; 22(6):815-21. PubMed ID: 11104169 [TBL] [Abstract][Full Text] [Related]
16. Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by irbesartan to ameliorate doxorubicin-induced hepatotoxicity. Kabel AM; Alzahrani AA; Bawazir NM; Khawtani RO; Arab HH J Infect Chemother; 2018 Aug; 24(8):623-631. PubMed ID: 29753615 [TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446 [TBL] [Abstract][Full Text] [Related]
18. Flucloxacillin induced delayed cholestatic hepatitis. Miros M; Kerlin P; Walker N; Harris O Aust N Z J Med; 1990 Jun; 20(3):251-3. PubMed ID: 2372276 [TBL] [Abstract][Full Text] [Related]
19. [Acute submassive cholestatic hepatitis after treatment with carbimazole. Presentation of a new case and review of the literature]. Moreno Sánchez D; Medina Asensio J; Colina Ruiz-Delgado F; Campos Cantero R; Crespo Rincón L; Belda Serna A Rev Esp Enferm Apar Dig; 1989 Sep; 76(3):273-6. PubMed ID: 2682839 [TBL] [Abstract][Full Text] [Related]